Exicure announces board member departures, transitions

CHICAGO, IL – Exicure , Inc. (NASDAQ:XCUR), a biotechnology company specializing in pharmaceutical preparations with a current market capitalization of $30.56 million, has reported changes to its Board of Directors, according to a recent 8-K filing with the Securities and Exchange Commission. The company’s stock has shown remarkable volatility, delivering a 663.64% return over the past six months.

Jiyoung Hwang has resigned from Exicure’s Board for personal reasons effective February 28, 2025. The company stated that her departure was not due to any disagreements over operations, policies, or practices.

Additionally, Paul Kang has stepped down from the Board as of March 3, 2025, also for personal reasons and without any operational disagreements. Prior to his resignation, Kang agreed on February 27, 2025, to provide transitional consulting services to Exicure for the next 12 months, following an understanding reached on February 1, 2025.

These board changes follow the appointment of Andy Yoo as Chief Executive Officer and President of Exicure, as previously disclosed on December 17, 2024. Yoo took over the CEO role from Kang, who stayed on as co-CEO for a short period to assist with the transition of his duties to Yoo.

Exicure’s corporate headquarters are located at 2430 N. Halsted St., Chicago, IL 60614, and the company is incorporated in Delaware. The firm operates under the name 03 Life Sciences since changing from its former name, Max-1 Acquisition Corp, on February 21, 2017.

The company’s common stock is traded on The Nasdaq Stock Market under the symbol XCUR. This report is based on statements from a press release.

In other recent news, Exicure, Inc. has announced several key developments that may interest investors. The company has successfully increased its stockholders’ equity to approximately $4.3 million, meeting the Nasdaq Stock Market’s minimum equity requirement for continued listing. This follows a period of financial maneuvering, including transactions with HiTron Systems Inc. and SangSangIn Investment & Securities Co., Ltd., which raised substantial funds through share sales. Exicure confirmed the receipt of $8.7 million from HiTron Systems Inc. as part of a Common Stock Purchase Agreement, further bolstering its financial position. Additionally, Exicure has appointed Chang Keun Choi and Minwoo Kang to its Audit Committee, with Kang taking on the role of Chair, enhancing the company’s governance structure.

These changes come after Exicure was previously notified by Nasdaq for not meeting the $2.5 million stockholders’ equity requirement, a situation that has now been resolved. The company’s compliance with Nasdaq’s listing rules was confirmed in a letter received on December 20, 2024, ensuring that its securities will continue to trade on the Nasdaq. Exicure’s efforts to maintain compliance and strengthen its governance are outlined in its recent SEC filings. Investors are advised to consider the associated risks as highlighted in the company’s Annual Report and other filings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.